NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis

Results from a Phase 2 NASH trial showing that LiverMultiScan (cT1) can detect drug efficacy in as little as 6 weeks to serve as an early go/no-go signal. cT1 differentiated responders, tracked changes, and correlated with histology and serum biomarkers, enabling sensitive, non-invasive longitudinal monitoring.